{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:38:32Z","timestamp":1780627112960,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","award":["2021YFF0703600"],"award-info":[{"award-number":["2021YFF0703600"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Marburg virus (MARV) is one of the principal members of the filovirus family, which can cause fatal hemorrhagic fever in humans. There are currently no prophylactic and therapeutic drugs on the market, and the high pathogenicity and infectivity of MARV make its research highly dependent on biosafety level 4 conditions, severely hindering the development of vaccines and therapies. Therefore, the development of medicines, such as MARV serological diagnosis, vaccines, and therapeutic antibody drugs, urgently needs a safe, convenient, and biosafety level 2 detection method to measure the neutralizing activity of MARV antibodies. To this end, we report a neutralization assay relying on a Rabies virus (RABV) reverse genetic operating system. We constructed infectious clones carrying the eGFP reporter gene and the full length of the original unmodified MARV GP gene. Based on the critical parameters of phylogenetic analysis, recombinant viruses targeting representative strains in the two major MARV lineages were successfully rescued. These pseudoviruses are safe in mice, and their inability to infect cells after being neutralized by antibodies can be visualized under a fluorescence microscope. We tested the system using the neutralizing antibody MR191. MR191 can significantly block the infection of BSR cells with pseudovirus. We compared it with the traditional lentivirus-type pseudovirus system to verify the system\u2019s credibility and obtained the same results as reported in the literature. In general, we have established a safe and visualized method for evaluating the neutralizing activity of MARV antibodies. Compared with traditional methods, it has the advantages of convenient operation, short cycle, and low cost. It is a candidate method that can replace actual viruses for a neutralization assay.<\/jats:p>","DOI":"10.3389\/fmicb.2022.927122","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T07:24:06Z","timestamp":1654759446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A Novel and Secure Pseudovirus Reporter System Based Assay for Neutralizing and Enhancing Antibody Assay Against Marburg Virus"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinhao","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimeng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/21505594.2022.2054760","article-title":"Pathogenicity and virulence of Marburg virus","volume":"13","author":"Abir","year":"2022","journal-title":"Virulence"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.meegid.2011.06.017","article-title":"Current perspectives on the phylogeny of Filoviridae","volume":"11","author":"Barrette","year":"2011","journal-title":"Infect. Genet. Evol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1084\/jem.20151267","article-title":"The role of fc-FcgammaR interactions in IgG-mediated microbial neutralization","volume":"212","author":"Bournazos","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/infdis\/jiy453","article-title":"Pan-Filovirus serum neutralizing antibodies in a subset of Congolese Ebolavirus infection survivors","volume":"218","author":"Bramble","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1007\/s12250-021-00405-8","article-title":"The application of a safe neutralization assay for Ebola virus using Lentivirus-based Pseudotyped virus","volume":"36","author":"Cao","year":"2021","journal-title":"Virol. Sin."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.1093\/infdis\/jiv182","article-title":"Comparison of the pathogenesis of the Angola and Ravn strains of Marburg virus in the outbred Guinea pig model","volume":"212","author":"Cross","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.vaccine.2020.11.042","article-title":"Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials","volume":"39","author":"Dulin","year":"2021","journal-title":"Vaccine"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of human antibody-mediated neutralization of Marburg virus","volume":"160","author":"Flyak","year":"2015","journal-title":"Cell"},{"key":"ref9","year":"2021"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","article-title":"Structural basis for Marburg virus neutralization by a cross-reactive human antibody","volume":"160","author":"Hashiguchi","year":"2015","journal-title":"Cell"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"key":"ref12","author":"Hevey","year":"2001"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1016\/j.jmb.2019.06.029","article-title":"Distinct genome replication and transcription strategies within the growing Filovirus family","volume":"431","author":"Hume","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/JVI.02172-15","article-title":"Macaque monoclonal antibodies targeting novel conserved epitopes within Filovirus glycoprotein","volume":"90","author":"Keck","year":"2016","journal-title":"J. Virol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e01865-18","DOI":"10.1128\/JVI.01865-18","article-title":"A recombinant rabies virus expressing the Marburg virus glycoprotein is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model","volume":"93","author":"Keshwara","year":"2019","journal-title":"J. Virol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","article-title":"The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding","volume":"23","author":"King","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1099\/0022-1317-83-9-2091","article-title":"Occupancy and mechanism in antibody-mediated neutralization of animal viruses","volume":"83","author":"Klasse","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e1963","DOI":"10.1002\/rmv.1963","article-title":"Current status on the development of pseudoviruses for enveloped viruses","volume":"28","author":"Li","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"n1988","DOI":"10.1136\/bmj.n1988","article-title":"Guinea reports West Africa's first ever case of Marburg virus disease","volume":"374","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"eaai8711","DOI":"10.1126\/scitranslmed.aai8711","article-title":"Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody","volume":"9","author":"Mire","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1038\/s41467-020-17892-0","article-title":"A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation","volume":"11","author":"Muruato","year":"2020","journal-title":"Nat. Commun."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12879-016-2045-6","article-title":"How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence","volume":"16","author":"Nyakarahuka","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3201\/eid2306.170047","article-title":"Isolated case of Marburg virus disease, Kampala, Uganda, 2014","volume":"23","author":"Nyakarahuka","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41591-020-0937-x","article-title":"Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model","volume":"26","author":"Park","year":"2020","journal-title":"Nat. Med."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.3201\/eid2612.202108","article-title":"Jansen van Vuren P. shedding of Marburg virus in naturally infected Egyptian Rousette bats, South Africa, 2017","volume":"26","author":"Paweska","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1007564","DOI":"10.1371\/journal.ppat.1007564","article-title":"Complete protection of the BALB\/c and C57BL\/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine","volume":"15","author":"Rahim","year":"2019","journal-title":"PLoS Pathog."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/v12090955","article-title":"Evaluation of the 50% infectious dose of human Norovirus Cin-2 in Gnotobiotic pigs: A comparison of classical and contemporary methods for endpoint estimation","volume":"12","author":"Ramesh","year":"2020","journal-title":"Viruses"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"00095-19","DOI":"10.1128\/MMBR.00095-19","article-title":"A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia","volume":"84","author":"Ristanovic","year":"2020","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"817200","DOI":"10.3389\/fmicb.2021.817200","article-title":"Pseudotyped vesicular stomatitis virus-severe acute respiratory syndrome-Coronavirus-2 spike for the study of variants, vaccines, and therapeutics Against coronavirus disease 2019","volume":"12","author":"Salazar-Garcia","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S679","DOI":"10.1093\/infdis\/jiy435","article-title":"Infection rates and risk factors for infection Among health workers During Ebola and Marburg virus outbreaks: A systematic review","volume":"218","author":"Selvaraj","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12889-019-6477-y","article-title":"Lowland grazing and Marburg virus disease (MVD) outbreak in Kween district, eastern Uganda","volume":"19","author":"Siya","year":"2019","journal-title":"BMC Public Health"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","article-title":"Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections","volume":"23","author":"Swenson","year":"2005","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"110689","DOI":"10.1016\/j.celrep.2022.110689","article-title":"Dynamic immunodominance hierarchy of neutralizing antibody responses to evolving GII.4 noroviruses","volume":"39","author":"Tohma","year":"2022","journal-title":"Cell Rep."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fcimb.2020.00444","article-title":"Comparison of VSV Pseudovirus and focus reduction neutralization assays for measurement of anti-Andes orthohantavirus neutralizing antibodies in patient samples","volume":"10","author":"Vial","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11262-014-1160-y","article-title":"Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene","volume":"50","author":"Wang","year":"2015","journal-title":"Virus Genes"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J. Virol. Methods"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"126993","DOI":"10.1016\/j.micres.2022.126993","article-title":"Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies","volume":"258","author":"Xiang","year":"2022","journal-title":"Microbiol. Res."},{"key":"ref39","first-page":"77","article-title":"Evaluation of Reed-Muench method in determination of activity of biological preparations","volume":"27","author":"Zamoiskii","year":"1956","journal-title":"Zh Mikrobiol. Epidemiol. Immunobiol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.927122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T07:24:13Z","timestamp":1654759453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.927122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":39,"alternative-id":["10.3389\/fmicb.2022.927122"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.927122","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"927122"}}